摘要
放射性肺损伤(RILI)是胸部肿瘤放射治疗最常见的并发症,它降低肿瘤的局控率并严重影响患者的生活质量。目前临床上对RILI的治疗限于激素和抗炎的对症治疗,但这些治疗副反应大且没有任何预防保护作用。本文根据近年来基于RILI的发生机制而兴起的预防性研究,重点从生物水平包括基因、干细胞治疗角度出发,探讨对RILI安全性更好、效果更佳、疗效更稳定的治疗。
Radiation-induced lung injury（RILI）is the most common complication of the radiotherapy for thoracic tumor.It can lower the ratio of local control and seriously affect the patients＇ quality of life.At present,the clinical management of RILI is not more than the use of glucocorticoid and anti-inflammatory agent for symptomatic treatments.These treatments do not have any preventive effect but cause much side reactions.In this paper,we review the data from the contigency researches on the mechanism of RILI,from the researches on gene therapy and stem cell-therapy,and we dicuss the more safe,more stable and more efficacious treatment of RILI.
出处
《生物医学工程学杂志》
EI
CAS
CSCD
北大核心
2010年第4期937-940,共4页
Journal of Biomedical Engineering
基金
国家自然科学基金资助项目(30870734)
关键词
放射性肺损伤
抗氧化剂
细胞因子抑制剂
基因治疗
间充质干细胞
Radiation-induced lung injury（RILI）
Antioxidant
Cytokine inhibitor
Genet therapy
Mesenchymal stem cell（MSC）
